ABBV/ENTA may already have the results of the SAPHIRE-1 and -2 studies (the first 2 of the 6 phase-3 trials in the initial NDA/MAA submission package); however, the companies haven't yet made a commitment to investors as to when these data will be released to investors. Please see #msg-92226409.
FWIW: Someone in my Twitter feed recently tweeted that he was in the SAPHIRE-1 study and had an SVR with no AEs. No way to know if this is true, but SAPHIRE-1 is essentially a safety study as noted in #msg-91739317.
Market Data 
Markets 
AI
